Leveraging Telemetry Expertise in Drug Discovery Studies
Project teams often ask about the utility of radiotelemetry in cardiovascular studies, where this effective paradigm can be a part of clients’ drug discovery and development plans.
The CorDynamics team has a vast level of expertise in this area. Our laboratories feature dedicated telemetry suites where we conduct studies in six small- and large-animal species. Over the last few years we have expanded the integration of our unique telemetry expertise into drug discovery studies. For cardiovascular efficacy interrogations in particular, telemetry studies provide a wealth of data and insight.
Taking atrial fibrillation as an example, we have used telemetry to facilitate the development of a chronic disease model. More specifically, we combine the measurement of atrial electrophysiological parameters with more traditional telemetry variables to optimize the interrogation of new chemical entities in the model.
Leveraging telemetry studies during the discovery phase also allows for the consecutive testing of multiple compounds to help clients determine the best molecules to move forward. The broad scope of data generated by these studies is indeed impressive, yet resource sparing.
Please feel free to contact me directly to discuss how radiotelemetry can facilitate efficacy assessments in addition to interrogating the safety profile of lead candidates.
Regards,
Dr. Michael Gralinski, CorDynamics CEO